The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper-Reference-Cited by-同舟云学术

The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

Published:2014-07 Issue:7 Volume:13 Page:751-755
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Fiorino Gionata,Girolomoni Giampiero,Lapadula Giovanni,Orlando Ambrogio,Danese Silvio,Olivieri Ignazio

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis;Wiens;Pharmacotherapy,2010

2. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis;Bansback;Dermatology,2009

3. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials;Peyrin-Biroulet;Clin Gastroenterol Hepatol,2008

4. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data;Bodger;Aliment Pharmacol Ther,2009

5. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis;Liu;Adv Ther,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials;Expert Opinion on Emerging Drugs;2023-01-02

3. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group;Pediatric Drugs;2021-12-16

4. Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey;Exploratory Research in Clinical and Social Pharmacy;2021-12

5. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study;Advances in Therapy;2021-11-23